Actuate Therapeutics, Inc. (ACTU)
NASDAQ:ACTU
Total Valuation
Actuate Therapeutics, Inc. has a market cap or net worth of $48.33M. The enterprise value is $40.60M.
Market Cap$48.33M
Enterprise Value$40.60M
Share Statistics
Actuate Therapeutics, Inc. has 23,925,852 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,925,852
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Actuate Therapeutics, Inc.’s return on equity (ROE) is -2.81 and return on invested capital (ROIC) is -270.08%.
Return on Equity (ROE)-2.81
Return on Assets (ROA)-1.58
Return on Invested Capital (ROIC)-270.08%
Return on Capital Employed (ROCE)-2.70
Revenue Per Employee0.00
Profits Per Employee-2.22M
Employee Count10
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Actuate Therapeutics, Inc. is ―. Actuate Therapeutics, Inc.’s PEG ratio is 0.09.
PE Ratio―
PS Ratio0.00
PB Ratio16.24
Price to Fair Value16.24
Price to FCF-6.70
Price to Operating Cash Flow-2.40
PEG Ratio0.09
Income Statement
In the last 12 months, Actuate Therapeutics, Inc. had revenue of 0.00 and earned -22.23M in profits. Earnings per share was -1.06.
Revenue0.00
Gross Profit0.00
Operating Income-22.50M
Pretax Income-22.23M
Net Income-22.23M
EBITDA-22.50M
Earnings Per Share (EPS)-1.06
Cash Flow
In the last 12 months, operating cash flow was -19.78M and capital expenditures -6.00, giving a free cash flow of -19.78M billion.
Operating Cash Flow-19.78M
Free Cash Flow-19.78M
Free Cash Flow per Share-0.83
Dividends & Yields
Actuate Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.43
52-Week Price Change-80.93%
50-Day Moving Average2.50
200-Day Moving Average5.28
Relative Strength Index (RSI)33.94
Average Volume (3m)170.53K
Important Dates
Actuate Therapeutics, Inc. upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Actuate Therapeutics, Inc. as a current ratio of 2.39, with Debt / Equity ratio of 10.70%
Current Ratio2.39
Quick Ratio2.39
Debt to Market Cap<0.01
Net Debt to EBITDA0.57
Interest Coverage Ratio-1.11K
Taxes
In the past 12 months, Actuate Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Actuate Therapeutics, Inc. EV to EBITDA ratio is -5.15, with an EV/FCF ratio of -6.03.
EV to Sales0.00
EV to EBITDA-5.15
EV to Free Cash Flow-6.03
EV to Operating Cash Flow-6.03
Balance Sheet
Actuate Therapeutics, Inc. has $8.13M in cash and marketable securities with $404.99K in debt, giving a net cash position of $7.73M billion.
Cash & Marketable Securities$8.13M
Total Debt$404.99K
Net Cash$7.73M
Net Cash Per Share$0.32
Tangible Book Value Per Share$0.38
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Actuate Therapeutics, Inc. is $10.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.67
Price Target Upside361.76% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast23.58%